Author

M. Zehner

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 4 Assay:proteomics· 4 Organism:human· 3 Research Focus:drug response / drug discovery· 2 Research Focus:cell type annotation· 1 Organism:mouse· 1 Organism:virus· 1

Frequent Co-Authors

C. Kreer· 5 shared F. Klein· 5 shared H. Gruell· 5 shared K. Vanshylla· 5 shared M. Koch· 4 shared M. Korenkov· 4 shared H. Janicki· 3 shared S. Becker· 3 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersImmunology

C. Kreer

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Dissecting the impact of somatic hypermutation on SARS-CoV-2 neutralization and viral escape

M. Korenkov, M. Zehner, H. Cohen-Dvashi, A. Borenstein-Katz, L. Kottege, H. Janicki, K. Vanshylla, T. Weber, H. Gruell, M. Koch, R. Diskin, C. Kreer, F. Klein

The paper reverts mutations in SARS-CoV-2 antibodies to study SHM's impact on neutralization, finding that some mutations are critical for neutralizing Omicron variants.

bioRxiv · May 9, 2023 · PreprintImmunology

Delineating antibody escape from Omicron sublineages

H. Gruell, K. Vanshylla, M. Korenkov, P. Tober-Lau, M. Zehner, F. Muenn, H. Janicki, M. Augustin, P. Schommers, L. E. Sander, F. Kurth, C. Kreer, F. Klein

This study evaluates antibody escape from Omicron sublineages by testing serum and monoclonal antibody activity against BA.1, BA.2, BA.2.12.1, and BA.4/5, revealing increased resistance in BA.4/5 and identifying promising neutralizing antibodies.

bioRxiv · Apr 6, 2022 · PreprintImmunology

No substantial pre-existing B cell immunity against SARS-CoV-2 in healthy adults

M. S. Ercanoglu, L. Gieselmann, S. Daehling, N. Poopalasingam, S. Detmer, M. Koch, M. Korenkov, S. Halwe, M. Kluever, V. Di Cristanziano, U. H. Janicki, M. Schlotz, J. Worczinski, B. Gathof, H. Gruell, , F. Klein

The paper analyzes B cell immunity in unexposed adults and finds no substantial pre-existing antibody or B cell response to SARS-CoV-2.

bioRxiv · Sep 8, 2021Immunology

Intranasal administration of a monoclonal neutralizing antibody protects mice against SARS-CoV-2 infection

S. Halwe, A. Kupke, K. Vanshylla, F. Liberta, H. Gruell, M. Zehner, C. Rohde, V. Kraehling, M. Gellhorn-Serra, C. Kreer, M. Kluever, L. Sauerhering, J. Schmidt, Z. Cai, F. Han, , S. Becker

This paper describes a monoclonal antibody, DZIF-10c, that effectively neutralizes SARS-CoV-2 and its variants when administered intranasally to mice, offering potential for topical treatment.

bioRxiv · Jun 9, 2021Microbiology

Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients

C. Kreer, M. Zehner, T. Weber, C. Rohde, S. Halwe, M. S. Ercanoglu, L. Gieselmann, M. Korenkov, H. Gruell, P. Schommers, K. Vanshylla, V. Di Cristanziano, H. Janicki, R. Brinker, A. Ashurov, , F. Klein

This study isolates potent SARS-CoV-2-neutralizing antibodies from COVID-19 patients as early as 8 days post-diagnosis and identifies precursor B cells in healthy individuals.

bioRxiv · Jun 12, 2020Immunology